Clinical Trials Logo

Citation(s)

Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer

Details for clinical trial NCT00004925